stoxline Quote Chart Rank Option Currency Glossary
  
iBio, Inc. (IBIO)
3  -0.27 (-8.26%)    12-01 15:59
Open: 2.8
High: 3.1334
Volume: 201,214
  
Pre. Close: 3.27
Low: 2.8
Market Cap: 4(M)
Technical analysis
2023-12-01 4:20:35 PM
Short term     
Mid term     
Targets 6-month :  5.24 1-year :  6.12
Resists First :  4.48 Second :  5.24
Pivot price 0.89
Supports First :  1.83 Second :  0.2
MAs MA(5) :  2.13 MA(20) :  0.74
MA(100) :  0.45 MA(250) :  0.79
MACD MACD :  0.5 Signal :  0.2
%K %D K(14,3) :  74.4 D(3) :  58.3
RSI RSI(14): 76.8
52-week High :  4.48 Low :  0.2
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ IBIO ] has closed below upper band by 8.3%. Bollinger Bands are 1855.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.14 - 3.16 3.16 - 3.17
Low: 2.76 - 2.78 2.78 - 2.8
Close: 2.97 - 3 3 - 3.03
Company Description

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Headline News

Fri, 01 Dec 2023
Is Ibio Inc (IBIO) Stock Worth a Buy Friday? - InvestorsObserver

Tue, 28 Nov 2023
Why SenesTech Shares Are Trading Lower By Around 50%? Here ... - Investing.com UK

Mon, 27 Nov 2023
iBio Announces Reverse Stock Split - Yahoo Finance

Thu, 16 Nov 2023
Virus-Like Particle Vaccine Market Latest Report 2023-2031 ... - GlobeNewswire

Wed, 15 Nov 2023
Impact Biomedical Inc. Files Current Report on Form 8-K - Yahoo Finance

Wed, 25 Oct 2023
iBio Inc. stock outperforms market despite losses on the day - MarketWatch

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android